Corcept Therapeutics Preliminary Settlement
Recovered:
$14 Million
A settlement has been reached in Melucci v. Corcept Therapeutics Incorporated, et al., Case No. 5:19-cv-01372-LHK (N.D. Cal.)
The settlement provides for the payment of $14 million to eligible class members. Lead plaintiff James Ferraro alleged violations of §§ 10(b) and 20(a) of the Securities Exchange Act of 1934 based on false and misleading misstatements that the company made that allegedly concealed from shareholders its off-label marketing of the drug Korlym.
Corcept Therapeutics' announcement of the settlement can be viewed here.
